AnalysisNews

SCNI today

$0.51+$0.01 (+2.85%)close Nov 11, 2026

Trend

DailyDowntrend (confirmed)

4 hourStrong Bullish

1 hourStrong Bullish

15 minStrong Bullish

5 minConsolidating

Daily trend turns up above $1.76

Key levels

Resistance$1.43

Resistance$1.06

Support$0.39

Latest news & SEC filings

EarningsNov 7, 2026Scinai Immunotherapeutics posts nine-month 2026 results, expands CDMO

DealNov 5, 2026Scinai Immunotherapeutics grows U.S. CDMO deal to $5.1M in base services

All SCNI news →

About Scinai Immunotherapeutics

Scinai Immunotherapeutics is an Israeli biopharmaceutical company with two main activities: providing manufacturing and development services to other drugmakers, and developing its own antibody-based therapies. Its pipeline focuses on NanoAb antibody fragments, including candidates aimed at IL-17 for psoriasis and psoriatic arthritis, plus an option to acquire PC111, a monoclonal antibody for rare skin conditions. It serves pharmaceutical and biotechnology clients and runs research and production sites in Israel.

Based on the company's 20-F filed Apr 1, 2026.

Nasdaq · Healthcare

Scinai Immunotherapeutics Ltd. (SCNI)

$0.51+0.01 (+2.85%)
HOLDGrade: DRisk: LOW
1D5D1M1Y5YMaxSign up for all timeframes
0.620.800.971.150.51Oct 9Oct 19Oct 27Nov 4
High0.55
Low0.46
Open0.50
Volume211K
Avg Vol762K
VWAP0.51
30d High1.33
30d Low0.44
30d Chg-61.15%
See full chart with real-time data

What Is the Price Target for SCNI?

SEPT Low Target

$0.00

SEPT Mid Target

$0.00

SEPT High Target

$0.00

Analyst Consensus

$0.00

Current: $0.50Upside: +0.0%Confidence: 20%Method: No Coverage

Is SCNI a Buy or Sell Right Now?

32
Investability Score
HOLD12-18 months
News summary · last 30 days
Oct 14▼ DownDilution2 articles
Scinai Immunotherapeutics announced a roughly $4 million private placement priced at $1.20 per ADS, alongside a warrant inducement transaction that reprices April 2026 warrants to $1.20 per ADS. Despite the dilution news, SCNI shares closed at $0.86, up 10.09% on the day, trading between a low of $0.75 and a high of $0.95 on volume of 859,027. The financing is dilutive to existing shareholders and was flagged as a bearish catalyst, though the stock's positive close suggests the market may have already priced in or absorbed the news. The direction signal from the news flow remains down given the dilution overhang.
Oct 13▲ UpContract2 articles
Scinai Immunotherapeutics announced a development and clinical manufacturing agreement worth $5.1 million with a biopharma company, which boosts its committed customer orders to $7.6 million, up 300% from year-end 2025. Despite this bullish contract news, the stock closed at $1.23, down 21.15% from the open of $1.56, with a trading range of $1.14 to $1.76 on heavy volume of 19.8 million shares. The sharp decline suggests that the positive news may have been overshadowed by broader selling pressure or profit-taking. The direction signal from the news is up, but the actual price action was strongly negative.
Critical news
Nov 3HIGHPrice move report
Oct 22HIGHPrice move report
Oct 20HIGHPrice move report
Oct 16HIGHPrice move report
Oct 15HIGHPrice move report
Oct 14HIGHPrice move report
Oct 14HIGHPrice move report
Oct 14HIGHPrice move report

Thesis

  • •Revenue growing 99.2% YoY with UNKNOWN trend — consistent growth.

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SCNI.

Start Free Trial →

Is SCNI Overvalued or Undervalued?

Valuation Verdict

N/A

Methods Used

P/B

Fair Value

$N/A

0

Moat Score

NONE

2/9

Piotroski Score

N/A

Altman Z-Score

What Is Smart Money Doing with SCNI?

Insider Signal

NEUTRAL

0 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

LOW

Signal: NEUTRAL

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

SCNI Growth Story

Revenue YoY

99.2%

3yr Revenue CAGR

N/A%

EPS Growth YoY

N/A

FCF Growth YoY

4.6%

Revenue Trend

UNKNOWN

Dark Pool Trades for SCNI

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for SCNI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

TimePriceSizeValueSide
21:26:07$0.481,500$$727BUY
21:26:03$0.491,400$$681BUY
21:26:03$0.491,100$$535BUY
21:06:01$0.501,000$$500SELL
20:51:40$0.513,549$$2KBUY

5 dark pool trades shown · $$4K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Scinai Immunotherapeutics Ltd. (SCNI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

Sign Up Free — Download AI Report PDF →

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

Compare SEPT with other platforms

SEPT vs TradingViewSEPT vs BloombergSEPT vs Unusual WhalesSEPT vs SpotGammaSEPT vs TrendSpiderAI Trading Platforms Compared
What is dark pool trading?How to read options flowGEX explainedSmart money trackingAI stock analysisEarn money on SEPT

About SEPT Investing

SEPT Investing tracks 13,000+ stocks with live charts, trend and key-level tracking, dark pool and options flow, insider and congress trades, SEC filings and news alerts.

Disclaimer: This page is for informational purposes only. It does not constitute financial advice. Past performance does not guarantee future results. Always do your own research before making investment decisions.

SCNI — frequently asked questions

What is SCNI stock price today?

Scinai Immunotherapeutics Ltd. (SCNI) is at $0.51, up 2.85% (+$0.01) at the Nov 11, 2026 close.

Why is SCNI stock moving today?

Latest SCNI news — Nov 7, 2026: Scinai Immunotherapeutics posts nine-month 2026 results, expands CDMO · Nov 5, 2026: Scinai Immunotherapeutics grows U.S. CDMO deal to $5.1M in base services

Why did SCNI stock move on Oct 14, 2026?

Scinai Immunotherapeutics announced a roughly $4 million private placement priced at $1.20 per ADS, alongside a warrant inducement transaction that reprices April 2026 warrants to $1.20 per ADS. Despite the dilution news, SCNI shares closed at $0.86, up 10.09% on the day, trading between a low of $0.75 and a high of $0.95 on volume of 859,027.

Did SCNI beat earnings?

SCNI last reported on Aug 24, 2026: EPS -$0.74.

Does SCNI pay a dividend?

SCNI does not currently pay a dividend.

What are SCNI support and resistance levels?

Support: $0.39. Resistance: $1.06, $1.43, $1.76.

What are insiders doing with SCNI?

Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

What is the latest news on SCNI?

Nov 7, 2026: Scinai Immunotherapeutics posts nine-month 2026 results, expands CDMO · Nov 5, 2026: Scinai Immunotherapeutics grows U.S. CDMO deal to $5.1M in base services